Patients10 Feb 2025 12:41
..... Frosties loadsoflolly? , nope, I'm a eggs & avacado man myself, carnivore diet. Hot morning Yoga at 5am with a follow up run in the hills, whatever the weather. Need a clear mind and tough thighs to crack this market.
As for IMM, this Tiger is in the bushes, ready to pounce, topped up, accumulating and keepin' a low profile. I'm not one to boast. When the time comes, I hope you & AATHOMZ able to serve yourself some vee-gan soy boy humble pie. Its about time in the market,
not timing the market.
Things are happening in the background, some more patience is needed. If you've seen what's been happening with the mild bounce this morning, that gives some indication. Yourself & Aathmoz will soon be smiling, but you'll both have slightly red
cheeks (wink winky nudgey nudge).
The main course of this report ( I'm considering launching a newsletter, might get a few sign ups from here?) Cor blimey, ladies and gents, it appears the Immupharma express IS about to leave the station,
and those still dithering & whining on the platform might soon find themselves running after a runaway gravy train. (The organic stuff, not bisto.)
We know that San Francisco conference, has laid the groundwork, the whispers are turning into
tiger roars, and an RNS looms large on the horizon. Yes, it’s a tad tardy, a little fashionably late to the soirée,
but as any good chef will tell you, the best soufflés take time to rise. Those in the know, know – and those who
don’t know, well, they’ll soon wish they had. The City’s movers, shakers, and dealmakers have been seen huddled
in corners, nodding, winking, and adjusting their braces – something's afoot, and it’s got "game-changer" written all over it.
The market has been tapping its watch, muttering about timeliness, but patience, dear friends, is the mother of all golden tickets.
This is not just any old biotech ; its a paradigm-shifting, cork-popping, portfolio-fattening moment of financial revelry!
Hence, those with an eye for the main chance, the ones who can spot a golden goose before it lays, are feathering their nests (check out todays buys).
The delay? Oh, a mere procedural tango, a touch of red tape and due diligence that ensures when this rocket lifts
off, it's not coming back down.the known knowns—those delectable morsels of certainty upon which my investment case rests.
Immupharma is progressing Lupuzor. Trust the science, its solid. Review the research on Pubmed, its bullet proof. The need is colossal,
and regulatory discussions are happening . Funding is secured, partnerships are in play, and a crucial RNS is en route.
These are facts, cold and hard, like a tax inspectors heart. Then we have the known unknowns—we know the RNS is coming,
but the precise details, the nitty-gritty of deal terms or trial pathways, remain unknown but will soon be known.
Now, onto the juicier parts—the unknown knowns, the things we don’t know we actual